



*ffw*

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 6, 2004.

*Andy P. E. Prince*  
Attorney for Applicants

PATENT  
Docket No. 3352.2.1.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Yao Xiong Hu	)	
		)	
Serial No.:	10/827,007	)	
		)	
Filed:	April 19, 2004	)	Art Unit:
		)	1645
		)	
For:	IMMUNOLOGICAL METHODOLOGY FOR DISCERNING	)	
	HUMAN PAPILLOMAVIRUS CONTEMPLATING	)	
	PEPTIDES FROM THE 37 EARLY CODING REGION OF	)	
	HPV 16	)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This Information Disclosure Statement discloses information which has come to the attention of Applicant and/or his attorneys and is being submitted so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.97(b), this Statement is being filed within three (3) months of the filing date of the above-identified application or before the mailing date of a first Action on the merits.

Neither Applicant nor his attorneys make any representation that any information disclosed herein may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103. Moreover, pursuant to 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement shall not be

construed as a representation that a search has been made or as an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).


In accordance with 37 C.F.R. § 1.98, this Information Disclosure Statement includes and is accompanied by:

1. A completed copy of Form PTO-1449 listing the patents, publications and other information being submitted for consideration; and
2. A legible copy of each patent, publication and other item of information in written form listed on the enclosed Form PTO-1449, excluding copies of references falling under the prior submission or citation exception of 37 C.F.R. § 1.98(d).

Various patents, publications, and other items of information listed on the accompanying Form PTO-1449 were previously cited by and/or submitted to the U.S. Patent and Trademark Office in Applicant's prior application (Application Serial No. 09/828,645 filed April 5, 2001 for "IMMUNOLOGICAL METHODOLOGY FOR DISCERNING HUMAN PAPILLOMAVIRUS", now issued as U.S. Patent No. 6,743,593), which is being relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98(d), copies of these patents, publications, and other items of information are not being submitted with this Statement.

DATED this 6<sup>th</sup> day of July, 2004.

Respectfully submitted,

  
\_\_\_\_\_  
Gary D.E. Pierce  
Attorney for Applicants  
Reg. No.: 38,019

Date: July 8, 2004

PATE PIERCE & BAIRD  
550 Park Side Tower  
215 South State Street  
Salt Lake City, Utah 84111  
Telephone: (801) 530-0330  
Facsimile: (801) 530-5955



<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (use several sheets if necessary)	<b>SERIAL NO.</b> 10/827,007	<b>ATTORNEY DOCKET NO.</b> 3352.2.1.3
	<b>FILING DATE</b> April 19, 2004	<b>GROUP ART UNIT</b> 1653
	<b>APPLICANT(S):</b> Yao Xiong Hu et al.	

**REFERENCE DESIGNATION****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	6,183,746	Feb. 6, 2001	Urban et al.	424/186.1	10/9/98
	A2	6,096,869	Aug. 1, 2000	Stanley et al.	530/351	3/22/96
	A3	5,932,412	Aug. 3, 1999	Dillner et al.	435/5	9/22/97
	A4	5,753,233	May 19, 1998	Bleul et al.	424/204.1	6/6/95
	A5	5,629,161	May 13, 1997	Muller et al.	435/7.1	12/23/94
	A6	5,629,146	May 13, 1997	Dillner et al.	435/5	6/25/91
	A7	4,777,239	Oct. 11, 1988	Schoolnik et al.	530/326	7/10/86

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION	
						YES	NO
	A8	WO 99/10744	March 4, 1999	Deutschland	G01N 33/569		X
	A9	EP 0 594 613	Nov. 28, 1991	Sweden	G01N 33/569	X	
	A10	EP 0344940	Dec. 12, 1989	European	C07K 7/06	X	
	A11	WO 87/01375	Mar. 12, 1987	France	C07K 15/00		X

**NON-PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT (Including Author, Title, Source, and Pertinent Pages)
	A12	Petter et al., <i>Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women</i> , Journal of General Virology, 81:701-8, 2000
	A13	Dreau et al., <i>Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression</i> , Annals of Surgery, 231(5):664-71, 2000

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



	A14	Wright et al., <i>HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer</i> , Journal of the American Medical Association, 283:81-6, 2000
	A15	Zumbach et al., <i>Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma</i> , International Journal of Cancer, 85:815-8, 2000
	A16	Mellin et al., <i>Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival</i> , International Journal of Cancer (Pred. Oncol.), 89:300-4, 2000
	A17	Frisch et al., <i>Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S.</i> , Cancer, 88(6):1464-9, 2000
	A18	Pirog et al., <i>Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma</i> , American Journal of Pathology, 157:1055-62, 2000
	A19	Cuzick et al., <i>A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions</i> , British Journal of Cancer, 83(5):561-5, 2000
	A20	Hagensee et al., <i>Seroprevalence of human papillomavirus type 16 in pregnant women</i> , Obstetrics and Gynecology, 94:653-8, 1999
	A21	Silins et al., <i>Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis</i> , Journal of General Virology, 80: 2931-6, 1999
	A22	Nobbenhuis et al., <i>Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study</i> , Lancet, 354:20-5; 1999
	A23	Sun et al., <i>Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma</i> , Cancer Epidemiology Biomarkers & Prevention, 8(10):935-40, 1999
	A24	Walboomers et al., <i>Human papillomavirus is a necessary cause of invasive cervical cancer worldwide</i> , Journal of Pathology, 189:12-19, 1999
	A25	Rice et al., <i>High risk genital papillomavirus infections are spread vertically</i> , Review of Medical Virology, 9:15-21, 1999
	A26	Meschede et al., <i>Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer</i> , Journal of Clinical Microbiology, 36(2):475-80, 1998
	A27	Arends et al., <i>Aetiology, pathogenesis, and pathology of cervical neoplasia</i> , Journal of Clinical Pathology, 51:96-103, 1998
	A28	Lowy et al., <i>Papillomaviruses: prophylactic vaccine prospects</i> , Biochimistrie et Biophysica Acta, 1423(1):M1-8, 1998
	A29	Clavel et al., <i>DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR</i> , Journal of Clinical Pathology, 51(1):38-43, 1998

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).





	A47	Hamsikova et al., <i>Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls</i> , Journal of Infectious Disease, 170:1424-31, 1994
	A48	Park et al., <i>Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses</i> , Journal of Virological Methods, 45:303-318, 307, 1993
	A49	Slawson et al., <i>Follow up papanicolau smear for cervical atypia: Are we missing significant disease?</i> , Journal of Family practice, 36(3):289-93, 1993
	A50	Jochmus et al., <i>Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies</i> , Molecular and Cellular Problems, 6:319-25, 1992
	A51	Lorincz et al., <i>Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types</i> , Obstetrics and Gynecology, 79:328-37, 1992
	A52	Schiffman MH, <i>Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia</i> , Journal of the National Cancer Institute, 84:394-8, 1992
	A53	Harlan et al., <i>Cervical cancer screening: who is not screened and why?</i> , American Journal of Public Health, 81:885-91, 1991
	A54	Kochel et al., <i>Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products</i> , Virology, 182:644-54, 1991
	A55	Hu YX, <i>Introduction and prospect of application of biogenetic engineering</i> , Guangzhou Medical Journal, 2:8-10, 1990
	A56	Hayward et al., <i>Who gets screened for cervical and breast cancer?</i> , Archives of Internal medicine, 148:1117-81, 1988.

Z:\ALL CLIENTS\3352 Impact Diagnostics\3352-2-1-3\3352-2-1-3 PAT-FIL-IDS PTO-1449 040708.wpd

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).